60: A high lactate dehydrogenase (LDH) level predicts for shorter survival following HLA-matched sibling bone marrow transplant (BMT) for patients with acute myelogenous leukemia (AML)

Abstract

Historically, the most important adverse risk factors for survival after BMT for AML are Active disease (ActDis), poor-risk cytogenetics, and older age. High serum LDH at the time of diagnosis is an adverse risk factor for survival for AML in the absence of BMT, but has not been explored as a risk factor in setting of BMT. We performed a multivariable analysis of these and other potential risk factors for overall and progression-free survival. From August 1992 to July 2005, we treated 87 patients with AML, who also had informative cytogenetic studies from the time of diagnosis, with high-dose busulfan-containing preparative regimens and an HLA-matched sibling BMT.